Roche Holding AG Share Price Berne S.E.

Equities

RO

CH0012032113

Pharmaceuticals

Delayed Berne S.E. 09:30:03 17/04/2024 pm IST 5-day change 1st Jan Change
237.4 CHF -2.51% Intraday chart for Roche Holding AG -0.47% -8.62%

Financials

Sales 2024 * 60.39B 67.83B 5,664B Sales 2025 * 63.83B 71.7B 5,987B Capitalization 193B 216B 18,076B
Net income 2024 * 13.27B 14.91B 1,245B Net income 2025 * 14.76B 16.58B 1,384B EV / Sales 2024 * 3.42 x
Net Debt 2024 * 13.77B 15.47B 1,292B Net Debt 2025 * 7.88B 8.85B 739B EV / Sales 2025 * 3.14 x
P/E ratio 2024 *
14 x
P/E ratio 2025 *
12.7 x
Employees -
Yield 2024 *
4.11%
Yield 2025 *
4.23%
Free-Float 88.91%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Roche Holding AG

Managers TitleAgeSince
Chief Executive Officer 49 01/03/01
Chairman 57 01/08/01
Director of Finance/CFO 57 01/11/01
Members of the board TitleAgeSince
Director/Board Member 72 03/15/03
Director/Board Member 59 -
Director/Board Member 66 01/96/01
More insiders
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
238.1 CHF
Average target price
277.5 CHF
Spread / Average Target
+16.56%
Consensus